Steigerwald Gordon & Koch’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-2,510
| Closed | -$242K | – | 120 |
|
|
2021
Q4 | $242K | Hold |
2,510
| – | – | 0.04% | 104 |
|
|
2021
Q3 | $218K | Hold |
2,510
| – | – | 0.04% | 109 |
|
|
2021
Q2 | $205K | Hold |
2,510
| – | – | 0.03% | 112 |
|
|
2021
Q1 | $239K | Buy |
+2,510
| New | +$239K | 0.04% | 93 |
|
|
2019
Q1 | – | Sell |
-2,510
| Closed | -$213K | – | 85 |
|
|
2018
Q4 | $213K | Hold |
2,510
| – | – | 0.06% | 80 |
|
|
2018
Q3 | $430K | Hold |
2,510
| – | – | 0.11% | 59 |
|
|
2018
Q2 | $324K | Buy |
+2,510
| New | +$324K | 0.09% | 68 |
|
|
2018
Q1 | – | Sell |
-2,510
| Closed | -$214K | – | 85 |
|
|
2017
Q4 | $214K | Buy |
+2,510
| New | +$214K | 0.06% | 79 |
|
|
2017
Q3 | – | Sell |
-2,671
| Closed | -$202K | – | 90 |
|
|
2017
Q2 | $202K | Buy |
+2,671
| New | +$202K | 0.06% | 83 |
|
|
2016
Q4 | – | Sell |
-3,203
| Closed | -$204K | – | 88 |
|
|
2016
Q3 | $204K | Hold |
3,203
| – | – | 0.07% | 67 |
|
|
2016
Q2 | $238K | Hold |
3,203
| – | – | 0.09% | 59 |
|
|
2016
Q1 | $214K | Hold |
3,203
| – | – | 0.08% | 58 |
|
|
2015
Q4 | $217K | Buy |
+3,203
| New | +$217K | 0.09% | 54 |
|
|
2015
Q2 | – | Sell |
-16,880
| Closed | -$328K | – | 52 |
|
|
2015
Q1 | $328K | Buy |
+16,880
| New | +$328K | 0.15% | 44 |
|